The Food and Drug Administration will permit Intarcia Therapeutics to request a public advisory committee hearing for its diabetes drug-eluting implant following two previous rejections over its kidney and heart risks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,